[CAS NO. 49671-76-3] ZLN005
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [49671-76-3]
Catalog
SLK-S7447
Brand
Selleck
CAS
49671-76-3
DESCRIPTION [49671-76-3]
Overview
| MDL | MFCD01560221 |
|---|---|
| Molecular Weight | 250.34 |
| Molecular Formula | C17H18N2 |
| SMILES | CC(C1=CC=C(C2=NC3=CC=CC=C3N2)C=C1)(C)C |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9946 mL | 19.9728 mL | 39.9457 mL |
| 5 mM | 0.7989 mL | 3.9946 mL | 7.9891 mL |
| 10 mM | 0.3995 mL | 1.9973 mL | 3.9946 mL |
| 50 mM | 0.0799 mL | 0.3995 mL | 0.7989 mL |
Description
ZLN005 is a potent and tissue-specific transcriptional activator.
Targets
| PGC-1α [1] |
In vitro
In L6 myotubes, ZLN005 increases expression of the PGC-1α gene and downstream genes by activation of AMP-activated protein kinase, and improves glucose uptake and fatty acid oxidation without obvious cytotoxicity. While ZLN005 does not has the same effects in rat primary hepatocytes, which suggests cell type–specificity.
In vivo
ZLN005 (15 mg/kg, p.o.) produces antihyperglycemia and antihyperlipidemia effects and increases insulin sensitivity in db/db mice but not lean mice.
Powered by Arctom Copyright © 2026 Arctom.
All rights reserved.